导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 0.58% | 2162/4743 |
| 近一周 | 0.84% | 834/5426 |
| 近一月 | -4.48% | 1741/5380 |
| 近一季 | 15.19% | 127/5198 |
| 近半年 | 0.99% | 1395/4898 |
| 近一年 | -13.39% | 3548/4372 |
| 近两年 | 25.61% | 2448/2937 |
| 近三年 | -15.14% | 2068/2237 |
| 成立以来 | -28.77% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.69% 2865/4961 |
-6.41% 3691/5312 |
- - |
- - |
| 2025 | 4.37% 3054/4813 |
3.12% 1183/3635 |
-1.36% 3149/4076 |
17.54% 2480/4524 |
-12.70% 4270/4813 |
| 2024 | -15.33% 2473/3463 |
-13.78% 2497/2808 |
-10.45% 2446/3014 |
21.45% 580/3129 |
-9.71% 2946/3463 |
| 2023 | -22.64% 1936/2656 |
-2.23% 1945/2280 |
-14.33% 2235/2385 |
-1.50% 535/2515 |
-6.23% 1680/2655 |
| 2022 | -23.52% 1142/2207 |
-16.40% 1128/1919 |
3.29% 1179/2016 |
-17.91% 1659/2113 |
7.91% 282/2208 |
| 2021 | -11.49% 1111/1822 |
-2.21% 597/1255 |
23.04% 119/1330 |
-16.75% 1402/1466 |
-11.63% 1611/1822 |
| 2020 | 76.50% 51/1250 |
11.95% 13/1028 |
37.77% 10/1067 |
2.64% 1000/1164 |
11.49% 535/1184 |
| 2019 | 47.08% 127/1092 |
28.91% 288/754 |
-3.33% 389/804 |
12.77% 30/850 |
4.65% 790/918 |
| 2018 | -10.57% 71/834 |
- - |
- - |
- - |
-13.81% 558/691 |
| 2017 | -9.40% 531/714 |
- - |
- - |
- - |
- - |
| 2016 | -20.89% 448/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.6144 | 32.25% |
| 景顺长城中证港股通创新药ETF | 1.6764 | 32.17% |
| 港股医疗 | 0.9539 | 31.90% |
| 港股医疗ETF | 1.4546 | 31.90% |
| 港股通医疗ETF工银 | 0.9639 | 31.81% |
| 港股通医疗ETF华宝 | 0.9752 | 31.64% |
| 万家中证港股通创新药ETF发起式联接A | 1.4069 | 31.06% |
| 万家中证港股通创新药ETF发起式联接C | 1.4061 | 30.98% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 嘉实中证港股通创新药指数发起式A | 0.8590 | 30.57% |
| 广发中证医疗ETF联接(LOF)A VS. 长安沪深300非周期A(740101) |